Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $271.86 | 7 | 75.9% |
| Education | $86.17 | 5 | 24.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $113.47 | 1 | $0 (2018) |
| Amgen Inc. | $103.41 | 3 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $74.25 | 4 | $0 (2021) |
| TESARO, Inc. | $23.10 | 1 | $0 (2018) |
| Baxter Healthcare | $17.70 | 1 | $0 (2022) |
| Celgene Corporation | $14.18 | 1 | $0 (2018) |
| Gilead Sciences, Inc. | $11.92 | 1 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $17.70 | 1 | Baxter Healthcare ($17.70) |
| 2021 | $74.42 | 4 | E.R. Squibb & Sons, L.L.C. ($62.50) |
| 2020 | $11.75 | 1 | E.R. Squibb & Sons, L.L.C. ($11.75) |
| 2018 | $254.16 | 6 | AstraZeneca Pharmaceuticals LP ($113.47) |
All Payment Transactions
12 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/10/2022 | Baxter Healthcare | Hillrom - Vest System Model 105 Home Care (Device) | Food and Beverage | In-kind items and services | $17.70 | General |
| Category: Airway Clearance Device | ||||||
| 12/21/2021 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Education | In-kind items and services | $21.42 | General |
| Category: Oncology | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 05/24/2021 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Education | In-kind items and services | $30.04 | General |
| Category: Oncology | ||||||
| 03/18/2021 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Education | In-kind items and services | $11.04 | General |
| Category: Oncology | ||||||
| 08/21/2020 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Education | Cash or cash equivalent | $11.75 | General |
| Category: Oncology | ||||||
| 09/25/2018 | Amgen Inc. | Kyprolis (Biological) | Food and Beverage | In-kind items and services | $33.92 | General |
| Category: Oncology | ||||||
| 07/25/2018 | Amgen Inc. | Kyprolis (Biological), XGEVA | Food and Beverage | In-kind items and services | $33.39 | General |
| Category: Oncology | ||||||
| 07/09/2018 | Celgene Corporation | Revlimid (Drug) | Food and Beverage | In-kind items and services | $14.18 | General |
| Category: Hematology / Oncology | ||||||
| 06/14/2018 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Food and Beverage | In-kind items and services | $113.47 | General |
| Category: Oncology | ||||||
| 05/08/2018 | TESARO, Inc. | ZEJULA (Drug) | Food and Beverage | In-kind items and services | $23.10 | General |
| Category: ONCOLOGY | ||||||
| 02/15/2018 | Amgen Inc. | Kyprolis (Biological), XGEVA | Food and Beverage | In-kind items and services | $36.10 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 43 | 1,947 | 28,177 | $2.1M | $466,778 |
| 2022 | 46 | 2,270 | 45,313 | $3.2M | $682,556 |
| 2021 | 53 | 2,598 | 78,299 | $3.4M | $756,110 |
| 2020 | 49 | 2,494 | 58,599 | $1.9M | $405,901 |
All Medicare Procedures & Services
191 procedure records from CMS Medicare Utilization — Page 1 of 8
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 15 | 7,800 | $1.1M | $337,238 | 29.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 151 | 364 | $85,002 | $21,959 | 25.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 97 | 201 | $137,886 | $20,063 | 14.6% |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 2023 | 14 | 4,255 | $89,355 | $10,117 | 11.3% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 236 | 960 | $59,520 | $9,920 | 16.7% |
| J0185 | Injection, aprepitant, 1 mg | Office | 2023 | 26 | 6,110 | $54,990 | $8,390 | 15.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 238 | 936 | $17,784 | $7,856 | 44.2% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 240 | 1,005 | $35,175 | $7,637 | 21.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 46 | 119 | $17,382 | $4,882 | 28.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 30 | 48 | $15,840 | $4,367 | 27.6% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 27 | 66 | $15,510 | $3,668 | 23.6% |
| 83520 | Measurement of substance using immunoassay technique | Office | 2023 | 32 | 172 | $31,132 | $2,911 | 9.4% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 70 | 237 | $24,885 | $2,796 | 11.2% |
| 82784 | Gammaglobulin (immune system protein) measurement | Office | 2023 | 26 | 287 | $15,498 | $2,616 | 16.9% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 31 | 54 | $16,416 | $2,581 | 15.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 31 | 31 | $10,354 | $2,415 | 23.3% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 28 | 48 | $16,032 | $2,395 | 14.9% |
| 99195 | Drawing of blood for a medical problem | Office | 2023 | 15 | 30 | $9,540 | $1,816 | 19.0% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 39 | 81 | $12,312 | $1,778 | 14.4% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 47 | 102 | $5,916 | $1,363 | 23.0% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 47 | 130 | $12,090 | $1,333 | 11.0% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 24 | 57 | $8,892 | $1,248 | 14.0% |
| 83550 | Iron binding capacity | Office | 2023 | 44 | 98 | $3,332 | $839.86 | 25.2% |
| 96411 | Administration of additional new drug or substance into vein using push technique | Office | 2023 | 12 | 19 | $5,339 | $813.96 | 15.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 11 | 13 | $2,821 | $797.03 | 28.3% |
About Dr. Jae Lee, MD
Dr. Jae Lee, MD is a Hematology & Oncology healthcare provider based in Eugene, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/22/2005. The National Provider Identifier (NPI) number assigned to this provider is 1154307080.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jae Lee, MD has received a total of $358.03 in payments from pharmaceutical and medical device companies, with $17.70 received in 2022. These payments were reported across 12 transactions from 7 companies. The most common payment nature is "Food and Beverage" ($271.86).
As a Medicare-enrolled provider, Lee has provided services to 9,309 Medicare beneficiaries, totaling 210,388 services with total Medicare billing of $2.3M. Data is available for 4 years (2020–2023), covering 191 distinct procedure/service records.
Practice Information
- Specialty Hematology & Oncology
- Location Eugene, OR
- Active Since 12/22/2005
- Last Updated 07/08/2007
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1154307080
Products in Payments
- IMFINZI (Drug) $113.47
- Kyprolis (Biological) $103.41
- OPDIVO (Biological) $74.25
- ZEJULA (Drug) $23.10
- Hillrom - Vest System Model 105 Home Care (Device) $17.70
- Revlimid (Drug) $14.18
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Eugene
Dr. Jeff Sharman, M.d, M.D
Hematology & Oncology — Payments: $745,823
Dr. Christopher Yasenchak, M.d, M.D
Hematology & Oncology — Payments: $114,099
James Butrynski, M.d, M.D
Hematology & Oncology — Payments: $22,425
Dr. Glenn Buchanan, Md, MD
Hematology & Oncology — Payments: $1,992
Dr. Barry Mckenzie, Md, MD
Hematology & Oncology — Payments: $281.16
Dr. James Fitzgibbons, Md, MD
Hematology & Oncology — Payments: $103.41